|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.26 USD | -2.45% |
|
+6.25% | -81.69% |
| Capitalization | 2.33B 2.01B 1.88B 1.75B 3.23B 210B 3.52B 21.97B 8.48B 99.15B 8.75B 8.57B 363B | P/E ratio 2025 * |
-4.07x | P/E ratio 2026 * | 9.97x |
|---|---|---|---|---|---|
| Enterprise value | 2.94B 2.53B 2.37B 2.21B 4.07B 264B 4.43B 27.68B 10.69B 125B 11.03B 10.79B 457B | EV / Sales 2025 * |
1.38x | EV / Sales 2026 * | 1.41x |
| Free-Float |
95.63% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Sarepta Therapeutics, Inc.
| 1 day | -2.45% | ||
| 1 week | +6.25% | ||
| Current month | +4.31% | ||
| 1 month | +37.41% | ||
| 3 months | +20.59% | ||
| 6 months | -43.70% | ||
| Current year | -81.69% |
| 1 week | 19.37 |  | 23 |
| 1 month | 15.94 | | 23 |
| Current year | 10.42 | | 129.84 |
| 1 year | 10.42 | | 131.31 |
| 3 years | 10.42 | | 173.25 |
| 5 years | 10.42 | | 181.83 |
| 10 years | 8 | | 181.83 |
| Manager | Title | Age | Since |
|---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 62 | 25/06/2017 |
Ryan Wong
DFI | Director of Finance/CFO | 46 | 15/07/2025 |
Ian Estepan
DFI | Director of Finance/CFO | 49 | 13/12/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
M. Wilsey
CHM | Chairman | 72 | 15/04/2015 |
| Director/Board Member | 86 | 31/05/2010 | |
Richard Barry
BRD | Director/Board Member | 66 | 01/06/2015 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 4.63% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.45% | +6.25% | -82.41% | -82.37% | 2.39B | |
| -0.44% | +7.76% | -22.78% | -9.43% | 3.52B | |
| +0.89% | +1.26% | +22.08% | - | 385M | |
| -0.65% | +4.63% | - | - | 84.04M | |
| -2.86% | -1.24% | +16.57% | +33.66% | 51.26M | |
| Average | -1.10% | +3.94% | -16.63% | -19.38% | 1.29B | |
| Weighted average by Cap. | -1.13% | +7.87% | -42.21% | -38.32% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.12B 1.83B 1.71B 1.59B 2.94B 191B 3.2B 20B 7.72B 90.27B 7.97B 7.8B 330B | 1.59B 1.37B 1.28B 1.2B 2.21B 143B 2.4B 15B 5.79B 67.68B 5.98B 5.85B 247B |
| Net income | -545M -469M -439M -409M -756M -49.07B -822M -5.14B -1.98B -23.18B -2.05B -2B -84.74B | 288M 247M 232M 216M 399M 25.89B 434M 2.71B 1.05B 12.23B 1.08B 1.06B 44.71B |
| Net Debt | 606M 521M 488M 455M 840M 54.52B 914M 5.71B 2.2B 25.75B 2.27B 2.23B 94.16B | -87.63M -75.33M -70.57M -65.77M -121M -7.89B -132M -825M -319M -3.72B -329M -322M -13.62B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 22.26 $ | -2.45% | 2,619,986 |
| 04/12/25 | 22.82 $ | +4.49% | 3,395,986 |
| 03/12/25 | 21.84 $ | +6.69% | 3,472,695 |
| 02/12/25 | 20.47 $ | +3.80% | 4,003,944 |
| 01/12/25 | 19.72 $ | -7.59% | 2,857,543 |
Delayed Quote Nasdaq, December 05, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SRPT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition